“This licensing agreement with NIC is an important step forward because it puts elements of a more comprehensive AML processing system under one roof,” says Hilary Eaton, PhD, Vor`s senior director of business development. “The combination of our next-generation treatment-resistant eHSCs with concurrent therapists such as this CD33 CAR-T has been designed to provide some patients with hematological malignancies with a unique enterprise solution that could transform outcomes and change the level of care.” “We are pleased to have completed the first part of the acquisition transaction by obtaining the exclusive global license from the Salzman Group for the development of R-107 for the treatment of coronavirus and COVID 19 infection. We will need approximately 10 weeks to complete the second part of the transaction, which will give Salzman Group time to complete audits of its financial statements for 2018 and 2019 and give Kalytera time to prepare and schedule a special shareholder meeting,” said Robert Farrell, President and CEO of Kalytera. “We anticipate that the general meeting of shareholders will take place in September and, assuming that disinterested shareholders approve the acquisition transaction, we will complete the acquisition on that date. PEKIN, China – CAMBRIDGE, Mass.—– Beigene, Ltd. (NASDAQ: BGNE); HKEX: 06160) and Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd., announced today that the companies have entered into an exclusive licensing agreement for BeiGene for the development, manufacture and marketing worldwide outside of the anti-COVID-19 antibodies studied by Singlomics, including DXP-593 and DXP-604. Singlomics uses single-celled sequencing of convalescent blood samples from convalescent patients with high COVID-19 flow and has identified several antibodies that have been shown to be highly effective in preclinical studies of neutralizing SARS-CoV-2, the virus responsible for COVID-19. BeiGene is a global biotechnology company focused on the discovery, development, production and commercialization of innovative drugs to improve treatment outcomes and patient access worldwide. Our more than 4,200 employees in China, the United States, Australia, Europe and elsewhere are working to accelerate the development of a diversified pipeline of new therapeutic drugs.
We are currently marketing two in-house oncology products: BTK BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We will also market or plan to market additional oncology products in China that have been licensed by Amgen Inc., Celgene Logistics S., a Bristol Myers Squibb (BMS) and EUSA Pharma company. To learn more about BeiGene, visit www.beigene.com and follow us on Twitter at @BeiGeneUSA. Before has its headquarters in Cambridge, Mass. and has a broad base for intellectual property, including in columbia University licenses, where the basic work was done by inventor and Pre-Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. In exchange for this license, Vincera Bayer will pay a pre-concession fee as well as commercial and development mileage payments. Taking into account the rights granted, we will also pay an annual fee for the commercial sale of double-digit licensed products for the net commercial sale of licensed products. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements about the future development and eventual marketing of the products granted; Any payments to Singlomics; The potential of licensed applicants commitments and the potential benefits of cooperation. Actual results may differ materially from the results indicated in the forward-looking statements, including BeiGene`s ability to demonstrate the effectiveness and safety of its candidates; Clinical outcomes for drug candidates who may not support development or marketing authorization; Measures taken by regulators with a